TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Feb 22, 2021 13:11 JST
Source:
Eisai
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
TOKYO, Feb 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo).
The Corporate Philanthropy Award was founded in 2003 with the aim of commending companies for their activities for social contribution that organically and sustainably utilize their management resources (human resources, know-how, technology, information, etc.) in order to solve social issues, and of passing on a fair, warm and vibrant society to the next generation by broadly disseminating those social contribution activities to society.
The award was presented to Eisai for its corporate philosophy of human health care (hhc) and its activities to realize the hhc philosophy, evaluating "a corporate culture and purposeful activities where employees demonstrate their true value toward the realization of a society in which people can live happily."
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In 2005, Eisai stipulated this philosophy as one of its Articles of Incorporation with the support of its shareholders. As an initiative to embody this hhc philosophy, Eisai recommends all officers and employees of the Eisai Group, including outside directors, to spend 1% of their business hours with patients and to engage in "socialization" to know their emotions. In addition, for developing and emerging countries, Eisai has continuously provided a treatment for lymphatic filariasis, which is one of the neglected tropical disease (NTDs), free of charge to endemic counties through the World Health Organization (WHO). Furthermore, Eisai has adopted the tiered-pricing model for its innovative new drugs, which sets multiple tiered prices according to the patient's income level and the insurance coverage that patients could afford. Thus, we are promoting various efforts to improve access to pharmaceutical products.
Award ceremony (left: Ms. Yoko Takahashi, director, the Japan Philanthropic Association, right: Keigo Kato, executive director, Knowledge Creation Dept., Eisai)
Eisai will make continuous efforts, based on the hhc philosophy, to further contribute to increasing the benefits of patients and their families around the world.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
More Press release >>
Latest Press Release
The 26th Hong Kong Forum marks successful completion
Dec 03, 2025 22:44 JST
Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Dec 03, 2025 11:30 JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Dec 03, 2025 00:01 JST
NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI
Dec 02, 2025 23:43 JST
Fujitsu develops new technology to support human-robot collaboration
Dec 02, 2025 23:26 JST
Fujitsu establishes international consortium to tackle disinformation/misinformation and new AI risks
Dec 02, 2025 22:55 JST
Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Dec 01, 2025 23:04 JST
Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Dec 01, 2025 22:43 JST
Fujitsu launches 'Fujitsu Accelerator Program for SPORTS' to create new value through Sports x Technology
Dec 01, 2025 22:14 JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST
MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST
Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST
More Latest Release >>